(Q46088168)

19 December 2017

title

Selection and analysis of HIV-1 integrase strand transfer inhibitor resistant mutant viruses (English)

1 reference

19 December 2017

author name string

Marc Witmer

series ordinal

1

1 reference

19 December 2017

Robert Danovich

series ordinal

2

1 reference

19 December 2017

publication date

13 March 2009

1 reference

19 December 2017

published in

Methods

1 reference

19 December 2017

volume

47

1 reference

19 December 2017

issue

4

1 reference

19 December 2017

page(s)

277-282

1 reference

19 December 2017

Mutational analysis of HIV-1 long terminal repeats to explore the relative contribution of reverse transcriptase and RNA polymerase II to viral mutagenesis

cites work

1 reference

https://api.crossref.org/works/10.1016%2FJ.YMETH.2009.02.025

TMC125 displays a high genetic barrier to the development of resistance: evidence from in vitro selection experiments

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YMETH.2009.02.025

Inhibitors of strand transfer that prevent integration and inhibit HIV-1 replication in cells

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YMETH.2009.02.025

4-Aryl-2,4-dioxobutanoic acid inhibitors of HIV-1 integrase and viral replication in cells

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YMETH.2009.02.025

Inhibitors of human immunodeficiency virus type I integration

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YMETH.2009.02.025

A naphthyridine carboxamide provides evidence for discordant resistance between mechanistically identical inhibitors of HIV-1 integrase

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YMETH.2009.02.025

Discovery of raltegravir, a potent, selective orally bioavailable HIV-integrase inhibitor for the treatment of HIV-AIDS infection

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YMETH.2009.02.025

Development of resistance against diketo derivatives of human immunodeficiency virus type 1 by progressive accumulation of integrase mutations

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YMETH.2009.02.025

Multiple mutations in human immunodeficiency virus-1 integrase confer resistance to the clinical trial drug S-1360.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YMETH.2009.02.025

Mutations associated with failure of raltegravir treatment affect integrase sensitivity to the inhibitor in vitro

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YMETH.2009.02.025

Selection of diverse and clinically relevant integrase inhibitor-resistant human immunodeficiency virus type 1 mutants

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YMETH.2009.02.025

Drug resistance profiles for the HIV integrase gene in patients failing raltegravir salvage therapy

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YMETH.2009.02.025

Production of acquired immunodeficiency syndrome-associated retrovirus in human and nonhuman cells transfected with an infectious molecular clone

7 January 2021

2 references

https://api.crossref.org/works/10.1016%2FJ.YMETH.2009.02.025

7 January 2021

https://api.crossref.org/works/10.1016%2FJ.YMETH.2009.02.025

inferred from DOI database lookup

7 January 2021

based on heuristic

Requirement of active human immunodeficiency virus type 1 integrase enzyme for productive infection of human T-lymphoid cells

1 reference

https://api.crossref.org/works/10.1016%2FJ.YMETH.2009.02.025

inferred from DOI database lookup

7 January 2021

based on heuristic

Identifiers

DOI

10.1016/J.YMETH.2009.02.025

1 reference

19 December 2017

1 reference

19 December 2017